| Autor: |
Young-soon Bae, Dong-Su Kim, Hyo Jung Seo, Je-Un Han, Hyung Jin Yoon, Jung Jin Hwang, Ju Jin Kim, Byung Hyo Woo, Hyo Jin Kim, Yoo Soon Jang, Seok Chang Han, Woong Hee Kim, Do Goo Kang, Hyun Jin Seo, Soo Young Lee, Sang June Jeon, Jungyu Yi, Jeongwoo Lee, Il Hyeok Seo, Se Hyun Kim, Woo Hyoung Kim, Na Hyung Park, Myeng Hyun Lee, Sung June Bae, Seung Hoon Lee, Gyu Ho Cho, Seong Han Kim, Seong Hwan Moon, Min Kyu Lee, Jae Won Choi, Kyu Young Lee, Dong Seok Huh, Dong Woo Kim, Kyung June Min, Hyoung Min Yoon, Hyunhye Kyung, Jieun Yang, Dasom Na, Sangbong Lee, Jaehwan Han, Yongho Kwak, Sei-Young Lee, Joo Young Nam, Byung-Ho Choi, Young-Kwan Moon, Won Do, Mooyoung Yoo, Sun-Sun Park |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
AAPPS Bulletin, Vol 32, Iss 1, Pp 1-23 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2309-4710 |
| DOI: |
10.1007/s43673-022-00063-2 |
| Popis: |
Abstract Boron neutron capture therapy (BNCT) has been attracting interest as a new radiation modality for cancer therapy because it can selectively destroy cancer cells while maintaining the healthy state of surrounding normal cells. Many experimental trials have demonstrated significant BNCT treatment efficacy using neutron beams from research reactors. However, nuclear reactor technology cannot be scaled to sites in hospitals delivering patient treatment. Therefore, compact accelerator-based neutron sources that could be installed in many hospitals are under development or have even been commissioned at many facilities around the world. In Korea, a radio-frequency (RF) linac-based BNCT (A-BNCT) facility is under development by DawonMedax (DM). It provides the highly efficient production of an epithermal neutron beam with an optimized neutron energy spectrum range of 0.1~10 keV. With a 2-mA 10-MeV proton beam from the accelerator, the irradiation port epithermal neutron flux is higher than 1 × 109 n/cm2⋅s. Comprehensive verification and validation of the system have been conducted with the measurement of both proton and neutron beam characteristics. Significant therapeutic effects from BNCT have been confirmed by DM in both in vitro and in vivo non-clinical trials. Further, during exposure to epithermal neutrons, all other unintended radiation is controlled to levels meeting International Atomic Energy Agency (IAEA) recommendations. Recently, the Korean FDA has accepted an investigational new drug (IND) and the first-in-human clinical trial of BNCT is now being prepared. This paper introduces the principles of BNCT and accelerator-based neutron sources for BNCT and reports the recent advances of DM A-BNCT facility which is the main part of this paper. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink